Business Wire

Twenty-Five Year Political Veteran Sam Myers, Jr. Named President of Direct Impact

24.9.2019 19:52:00 EEST | Business Wire | Press release

Share

BCW (Burson Cohn & Wolfe), a leading global communications agency, today announced that Sam Myers, Jr., has been named President of Direct Impact (DI), the nation's leading grassroots campaign firm and member of BCW Group. Myers is based in Washington, D.C., and is charged with building DI’s industry-leading work in developing local market campaigns that drive communities to take action around various public affairs, public education and corporate reputation issues.

“I am thrilled that Sam will be leading DI,” said Chris Foster, President of BCW North America. “His more than two decades of political campaign experience and having served at the highest levels of government will be invaluable to clients that are navigating increasingly complex communications and legislative environments.”

Myers has served in two presidential administrations and worked on six presidential campaigns. From 2009 to 2017 he served in the Obama administration, in multiple leadership roles. For the U.S. Department of Education, his efforts in the Office of the Secretary and as head of Office of the White House Liaison helped put in place policies that supported narrowing the skills gap, job creation, healthy eating in schools and America’s College Promise.

Myers also spearheaded change management and communication for Department of Commerce’s move to a department-wide, enterprise services model. For the White House, he led delegations to the Vatican, UN General Assembly and Aspen Ideas Festival. In the Clinton administration, he served as an advance staffer for President Clinton and as a Defense Fellow at the U.S. Department of Defense.

Upon leaving the public sector in 2017, Myers transitioned to Brooklyn-based Huge, Inc., working in a series of roles, most recently Vice President for Partnerships and Development, where he developed thought leadership platforms around autonomous vehicles, aerospace, maternal health and the future of work; created partnerships at SXSW, CES and Cannes, among others; and drove strategic growth for Huge’s Washington, D.C. office and global business. He then served as a Senior Vice President for San Francisco-based The OutCast Agency, charged with expanding the agency’s Washington, D.C. presence.

“Across my 25 years in campaigns, politics and public affairs, the one constant I have seen is how powerful it is when companies and organizations connect with people on their own turf about the issues they care about the most,” said Myers. “I have watched and marveled at the extraordinary work DI has done in this area and I jumped at the chance to lead this great team.”

Myers’ campaign experience includes working on Hillary for America 2016; Obama for America; John Edwards for President 2008; Kerry Edwards 2004; Gore/Lieberman 2000; Clinton/Gore 1996 and founding DC based Myers Strategies in 2004, focused on effective messaging through national grass roots events.

About Direct Impact

Founded in 1988, Direct Impact (DI) is a wholly owned subsidiary of BCW and a member of the WPP family. DI is a premier grassroots communications firm, specializing in public affairs, public education and corporate reputation campaigns. DI provides a complete range of services essential to conducting successful localized campaigns, focusing on legislative battles as well as corporate branding challenges across the country. DI has led winning, community-driven campaigns for more than half of the Fortune 50, as well as major trade associations and coalitions.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media: Catherine Sullivan
Phone: 212.601.3205
Email: Catherine.Sullivan@bcw-global.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 10:10:00 EEST | Press release

LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The

Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 10:00:00 EEST | Press release

Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 years, she has led global teams to achieve a 100% success rate from Phase 3 development through to FDA approval for multiple programs spanning oncology, immunology and respiratory medicine. In addition, she raised funds of around $400M as founder and CEO. Across her career she has contributed to 20 drug approvals, engaging

TOHKnet and Adtran conduct Japan’s first 50G PON trial on a live network4.8.2026 10:00:00 EEST | Press release

Adtran today announced that TOHKnet has completed Japan’s first live network trial demonstrating the coexistence of 50G PON, XGS-PON and EPON on a single fiber. Conducted in Sendai using Adtran’s SDX 6400 Series OLT, the demo showed how the platform enables three generations of PON technology to operate together in a live service environment. The results highlight a realistic path for operators to introduce 50G PON capacity while maintaining continuity for existing services, maximizing the value of deployed fiber assets and reducing the complexity and disruption typically associated with network upgrades. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260803353435/en/ Adtran’s SDX 6400 Series is helping TOHKnet demonstrate how Japan’s operators can migrate to 50G PON without disrupting existing PON services. “As demand for digital services continues to grow, this trial is a key milestone for the future of fiber access in Jap

“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 10:00:00 EEST | Press release

The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the project continues to captivate audiences through its

Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer4.8.2026 10:00:00 EEST | Press release

Evexta Bio S.A., a precision oncology company, founded by Truffle Capital (founder of Abivax and Carvolix), and focused on the discovery and development of targeted therapies, today announced a clinical collaboration and supply agreement with plans to initiate a Phase 1b study combining its lead investigational compound, rupitasertib, with Roche’s investigational compound giredestrant, a selective estrogen receptor degrader (SERD), for the treatment of ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer. Rupitasertib, is a first-in-class oral dual-node PI3K/AKT/mTOR (PAM) pathway inhibitor, which selectively inhibits S6K and AKT1/3. Rupitasertib was purposefully and rationally designed to target S6K for potent PAM inhibition and AKT1/3 to block the AKT compensatory feedback loop, while sparing AKT2 to avoid hyperglycemia, which we believe will lead to a superior efficacy and safety profile compared to other PAM pathway inhibitors. Under the terms of the agreement, Roche will s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye